Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings outcomes immediately.
Reported gross sales elevated 6.8% year-over-year to $24 billion. Operational gross sales had been up 5.4%.
GAAP internet earnings rose 91% to $5.2 billion, or $2.12 per share, in comparison with final 12 months. Adjusted EPS grew 16% to $2.80.
Income and earnings beat estimates.
The corporate raised its gross sales steerage for the total 12 months of 2025 and now expects reported gross sales to be $93.5-93.9 billion. It reaffirmed its steerage for adjusted EPS, which is predicted to be $10.80-10.90.
In a separate launch, JNJ introduced its intent to separate its Orthopaedics enterprise to enhance strategic focus and drive shareholder worth. The transaction would create a standalone orthopaedics enterprise named DePuy Synthes. The corporate has appointed Namal Nawana as Worldwide President, DePuy Synthes, efficient instantly. It expects to finish this transaction inside 18 to 24 months, based mostly on sure situations.
JNJ additionally declared a money dividend of $1.30 per frequent share for the fourth quarter of 2025, payable on December 9, 2025 to shareholders of file as of November 25, 2025.
